louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06711406: The Effect of Attention on Postural Control
Official title: The Effect of Attention on Postural Control
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: ADHD - Attention Deficit Disorder with Hyperactivity
Postural Instability
Keywords: ADHD
Posture
Attention
Balance
Dual task
Lead sponsor: Yeditepe University
Sponsor class: OTHER
First posted: 2024-12-02
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This study was planned with healthy young volunteers (18-30-year-olds) who have the potential to have ADHD. Our target population was university students.

Brief summary: Objective: This study investigates the relationship between postural control and sustained attention in individuals with probable ADHD. Motor control issues, including balance deficits, are observed in 30-50% of children with ADHD. These deficits may extend into adulthood, yet research on postural control in adults with ADHD is limited. This study aims to address this gap by exploring the connection between attention and postural stability in adults with ADHD.

Background: ADHD is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity, affecting both children and adults. Studies have shown that postural control relies on coordinated functioning of sensory and neuromotor systems, which ADHD may impact. In children, postural challenges are more pronounced in conditions requiring complex sensory integration. However, research on adults with ADHD is sparse, though preliminary findings suggest postural instability and possible links to cerebellar differences.

Methodology: The study evaluates sustained attention and postural control in adults with ADHD, using the Adult ADHD Screening Scale (ASRS-5) and postural stability assessments under dual-task conditions. By examining attention-driven postural responses, the study contributes to developing therapeutic balance protocols for individuals with ADHD.

Hypotheses:

H0: No relationship exists between postural control and sustained attention in individuals with ADHD.

H1: A relationship exists between postural control and sustained attention in individuals with ADHD.

Significance: This study contributes to a better understanding of the neurophysiological links


Eligibility criteria: Inclusion Criteria:

* Volunteers between 18-30-year-olds
* Not having any problems with balance

Exclusion Criteria:

* Having a physical injury in the last 6 months (such as ankle sprain)
* Having any neurological disorder
* Exercising regularly for the last 12 months

Primary outcomes:
measure: Postural Control: Prokin PK 252.
timeFrame: 30 minutes
Secondary outcomes:
measure: Cognitive tests: Sustained Attention to Response Task (SART):
timeFrame: 5 minutes
Other outcomes:
Locations:
city: İstanbul
country: Turkey
facility: Yeditepe University
state: Ataşehit
Study officials:
affiliation: Yeditepe University
name: Çiğdem Yazıcı Mutlu, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01060306: Optical Coherence Tomography Evaluation of a Biodegradable Polymer-based Drug-eluting Stent
Official title: Prospective Optical cohereNce Tomography Evaluation of neoINtimal Coverage of a biodegrAdable Polymer-based Drug-eluting Stent
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Coronary Artery Disease
Lead sponsor: Ospedale Santa Maria Goretti
Sponsor class: OTHER
First posted: 2010-02-02
Enrollment: 0
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention on the left anterior descending artery with a Biomatrix stent placement or on the left circumflex artery with a Gazelle stent placement

Brief summary: PONTINA aims at assessing by optical coherence tomography the neointimal coverage of the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) after full drug elution and polymer biodegradation (6 months), at one month after this time-point (7 months) and, as a comparator, of its bare metal stent counterpart (Gazelle stent) at 1 month after implantation.


Eligibility criteria: Inclusion Criteria:

* age \>50 years
* de novo lesion
* lesion length \<24 mm
* reference vessel diameter 3 mm

Exclusion Criteria:

* low compliance to dual antiplatelet therapy
* life expectancy \<1 year
* allergy to any drug or substance use prior, during or after percutaneous coronary intervention
* chronic renal insufficiency
* low left ventricle ejection fraction (\<35%)
* recent acute myocardial infarction
* previous coronary intervention
* off-label indication to stenting
* participation in another investigation
* refusal to participate to the study

Primary outcomes:
measure: Assessment of neointimal coverage of the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) after full drug elution and polymer biodegradation
timeFrame: 6 months
Secondary outcomes:
measure: Assessment of neointimal coverage of the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) one month after full drug elution and polymer biodegradation
timeFrame: 7 months
measure: Comparison of neointimal coverage of the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) one month after full drug elution and polymer biodegradation and of its bare metal stent counterpart (Gazelle) one month after implantation
timeFrame: 7 months
measure: Comparison of the neointimal coverage of the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) after full drug elution and polymer biodegradation (6 months) and at one month after this time-point (7 months)
timeFrame: 7 months
Other outcomes:
Locations:
city: Latina
country: Italy
facility: UOC Emodinamica e Cardiologia Interventistica - Ospedale Santa Maria Goretti
Study officials:
References:
Clinical trial NCT01256606: Prenatal Test for Fetal Aneuploidy Detection
Official title: Investigational Study of a Prenatal Diagnostic Test for Fetal Aneuploidy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Aneuploidy
Trisomy 21
Lead sponsor: Roche Sequencing Solutions
Sponsor class: INDUSTRY
First posted: 2010-12-08
Enrollment: 4000
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnant women planning to undergo chorionic villus sampling or amniocentesis for fetal genetic evaluation

Brief summary: The purpose of this study is to develop and evaluate a blood test for pregnant women for detection of fetal aneuploidy.


Eligibility criteria: Inclusion Criteria:

* Subject is 18yrs or older
* Subject has a singleton pregnancy
* Subject is planning to undergo chorionic villus sampling (CVS) and/or amniocentesis with current pregnancy
* Subject is able to provide consent

Exclusion Criteria:

* Subject is pregnant with more than one fetus
* Subject (mother) has known aneuploidy
* Subject has active malignancy requiring major surgery or systemic chemotherapy or has a history of metastatic cancer.
* Subject has already undergone CVS or amniocentesis during current pregnancy prior to study enrollment.

Primary outcomes:
measure: Comparison of blood test to results from chorionic villus sampling or amniocentesis for fetal aneuploidy detection
timeFrame: 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: Oakland
country: United States
facility: East Bay Perinatal Medical Associates
state: California
city: Sacramento
country: United States
facility: Prenatal Diagnosis of Northern California
state: California
city: San Diego
country: United States
facility: University of California - San Diego
state: California
city: San Francisco
country: United States
facility: University of California - San Francisco
state: California
city: Atlanta
country: United States
facility: Atlanta Perinatal Consultants
state: Georgia
city: Milwaukee
country: United States
facility: Medical College of Wisconsin
state: Wisconsin
Study officials:
affiliation: Ariosa Diagnostics
name: Ken Song, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00437606: A Study of the Pharmacokinetics/Pharmacodynamics of GK Activator (2) in Type 2 Diabetes Patients With Hepatic Impairment.
Official title: A Nonrandomized, Open Label Study to Examine the Effect of Hepatic Impairment on the Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.'
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Diabetes Mellitus, Type 2
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2007-02-21
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will investigate the effect of hepatic impairment on the pharmacokinetics, pharmacodynamics, safety and tolerability of GK Activator (2) in type 2 diabetes patients with mild and moderate hepatic impairment. Patients with type 2 diabetes, and with normal hepatic function, or mild or moderate hepatic impairment, will receive a single dose of GK Activator (2) 100mg po before breakfast, for assessment of pharmacokinetic, pharmacodynamic and safety parameters. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.


Eligibility criteria: Inclusion Criteria:

* adult patients, 18-75 years of age;
* type 2 diabetes;
* normal hepatic function, or mild or moderate hepatic impairment.

Exclusion Criteria:

* type 1 diabetes, or latent autoimmune diabetes in adults;
* diabetic neuropathy, retinopathy or nephropathy;
* treatment with insulin or PPAR gamma agonist within 6 weeks of screening;
* clinically significant cardiovascular disease.

Primary outcomes:
measure: AUCo-inf and Cmax of plasma and urine GK Activator (2) and M4. AUC0-6 of plasma glucose.
timeFrame: Days 1, 8 and 15
Secondary outcomes:
measure: tmax, AUC0-6, AUC0-last, t1/2, CL/F, Ac, CL for GK Activator (2) and M4. Cmin, Cmax, tmax and tmin of plasma glucose.
timeFrame: Days 1, 8 and 15
measure: AEs, laboratory parameters.
timeFrame: Throughout study
Other outcomes:
Locations:
city: Berlin
country: Germany
city: Kiel
country: Germany
city: Bratislava
country: Slovakia
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT05580406: Outreach to Reduce Depression Disparities
Official title: Outreach to Reduce Depression Disparities
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression
Lead sponsor: Kaiser Permanente
Sponsor class: OTHER
Collaborators: name: Henry Ford Health System
First posted: 2022-10-14
Enrollment: 322
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Previous research by Mental Health Research Network (MHRN) investigators and others demonstrates that online messaging and other telehealth technologies can effectively and efficiently address premature discontinuation of depression treatment. These interventions, however, have focused on adherence after treatment initiation and have been tested primarily in non-Hispanic white populations. Less is known about the acceptability and effectiveness of different communication modalities (online messaging, mailed letters, telephone) among racial and ethnic minority populations. Implementation of electronic-Health (eHealth) technologies must take care not to exacerbate health disparities.

This clinical trial involves a pilot trial to evaluate a population-based outreach program to improve rates of depression treatment initiation among traditionally underserved racial and ethnic groups. This pilot work intends to inform a subsequent full-scale pragmatic trial to examine impact on health disparities.


Eligibility criteria: Inclusion Criteria:

* New diagnosis of major depressive disorder or dysthymic disorder at a primary care visit ("new" defined as no depression diagnosis, psychotherapy visit or filled antidepressant prescription in the prior year)
* Continuously enrolled in the participating health system for 365 days prior to the eligible diagnosis (to assure capture of prior diagnoses or treatments)
* Patients Health Questionnaire-9 (PHQ-9) depression score of 10 or more within 14 days before to 7 days after the eligible diagnosis
* No filled prescription for any antidepressant medication OR psychotherapy visit attended within 30 days of the eligible diagnosis\*
* No recorded PHQ-9 depression score less than 5 since the eligible diagnosis
* At least 18 years of age or older

Exclusion Criteria:

* Diagnosis of schizophrenia or bipolar disorder in the prior 2 years
* Not registered to use Electronic Health Record (EHR) patient portal
* Previously requested to not be contacted for research

Primary outcomes:
measure: Initiation of formal depression treatment
timeFrame: within 60 days of randomization
Secondary outcomes:
Other outcomes:
Locations:
city: Honolulu
country: United States
facility: Kaiser Permanente, Hawaii Market
state: Hawaii
city: Detroit
country: United States
facility: Henry Ford Health
state: Michigan
Study officials:
References:
Clinical trial NCT06966206: Multiprofen-CC to Reduce Pain in Hand Arthritis
Official title: Multiprofen-CC to Reduce Pain in Hand Arthritis (MRP-HAND): A Crossover Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Hand Osteoarthritis
Keywords: hand osteoarthritis
osteoarthritis
arthritis
topical
multiprofen
Lead sponsor: McMaster University
Sponsor class: OTHER
Collaborators: name: The Research Institute of St Joe's Hamilton
First posted: 2025-05-11
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: 2x2 crossover randomized placebo-controlled trial
Primary purpose: TREATMENT

Brief summary: This clinical trial aims to find out if using 1 gram of Multiprofen-CC cream on the hands three times a day for 4 weeks can help reduce pain in adults with hand osteoarthritis, compared to a placebo (a cream with no active medicine). The research team will also look at how Multiprofen-CC affects hand function, opioid use, and how patients feel about their overall improvement. In addition, the research team will keep track of any side effects.

Participants will:

* Use both Multiprofen-CC and a placebo (a cream with no active medicine) during the study, in a random order.
* Be asked to apply 1 gram of cream to their hands three times a day for 2 weeks, following the manufacturer's instructions.
* Attend a visit before starting the study, after 2 weeks, and after 6 weeks.
* Report any symptoms they experience during the study.


Eligibility criteria: Inclusion Criteria:

* Adults (18+)
* Have been diagnosed with hand osteoarthritis according to American College of Rheumatology criteria
* Experience pain and/or loss of function in one or both hands that interferes with daily life
* Provide informed consent

Exclusion Criteria:

* Unable to consent
* Unable or unwilling to follow study protocol
* Known allergy or contraindication to any of the study drugs or their ingredients
* Have open wounds/cuts and/or skin conditions on the hand area
* Pregnant or breastfeeding
* History of impaired kidney or liver function
* Rheumatoid or other inflammatory arthropathy
* Hand surgery within the past 6 months or planned within the study period.
* Use daily opioids (other than short acting codeine) for a chronic pain condition other than hand arthritis

Primary outcomes:
measure: Pain intensity
timeFrame: baseline [week 0] and weeks 2, 4, and 6
Secondary outcomes:
measure: Pain interference
timeFrame: weeks 2, 4 and 6
measure: Hand function
timeFrame: weeks 2, 4 and 6
measure: Patients reported improvement
timeFrame: weeks 2, 4 and 6
measure: Safety - adverse events
timeFrame: through study completion, an average of 6 weeks
Other outcomes:
measure: Thumb Disability (exploratory outcome)
timeFrame: weeks 2, 4, and 6
Locations:
city: Hamilton
country: Canada
facility: St. Joseph's Healthcare Hamilton
state: Ontario
Study officials:
affiliation: McMaster University
name: Carolyn Levis, MD, MSc, FRCS(C)
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01247506: Different Genetic Features Associated With Hepatic Carcinogenesis
Official title: Identification of Survival-related microRNAs in Hepatocellular Carcinoma
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hepatocellular Carcinoma
Keywords: microRNA
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
Collaborators: name: National Science and Technology Council, Taiwan
First posted: 2010-11-24
Enrollment: 160
Sex: ALL
Minimum age (years): 45
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: A total of 160 patients with histologically proven HCC were collected by Dr. Po-Huang Lee's Lab (The Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan)

Brief summary: The purpose of this study is to identify different genetic features in hepatocellular carcinoma. It will assist in predicting individual risks of disease progression and would help to clarify pathophysiological mechanisms of HCC.

Detailed description: Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths in Taiwan. HCC normally develops as a consequence of underlying liver disease and is most often associated with cirrhosis. Surgical resection and liver transplantation are current best curative options to treat HCC. However, recurrence or metastasis is quite common in patients who have had a resection and survival rate is 30% to 40% at 5 years postoperatively.

MicroRNAs, small non-coding RNA, act as endogenous RNA interference by post-transcription regulation. Recent studies suggest that microRNAs may act as tumor suppressors or oncogenes and altered microRNA expression levels may play an important role in the cancer initiation and progression. Several studies, including ourselves, have shown that specific microRNAs are aberrantly expressed in malignant HCC tissues compared to normal counterpart. Although many microRNA profiling studies were done to diagnose hepatocarcinogenesis, data about prognostic significances for postsurgical survival are very limited. The main point of this study is to develop a predictive signature for postsurgical survival in HCC patients.

Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of hepatocellular carcinoma

Exclusion Criteria:

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Po-Huang Lee, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT03284606: Effect of Taping in the Hemiplegic Patient With a Deficit of the Footbrowers
Official title: A Pilot Study of the Effect of Taping in the Hemiplegic Patient With a Deficit of the Footbrowers
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Hemiplegia
Lead sponsor: University Hospital, Toulouse
Sponsor class: OTHER
Collaborators: name: Groupement Interrégional de Recherche Clinique et d'Innovation
First posted: 2017-09-15
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A majority of people undergoing rehabilitation following a stroke have a deficit of the dorsal flexors of the foot. The implementation of rehabilitation techniques in accordance with the recommendations of learned societies is not sufficient to compensate for this deficit. Also Kinesio Taping's method of Dr. Kenzo Kase has caught our attention by its action on muscle, joint, circulatory and pain functions.

The use of taping would increase the duration of stimulation of the muscles of the dorsiflexors of the foot which would facilitate the motor recovery.

Data from the literature do not support the conclusion that taping is effective, but no studies evaluating the efficacy of this technique in the foot-lift deficiency of the hemiplegic patient have been found.

The investigators hypothesize that the use of taping in conjunction with common rehabilitation for hemiplegic patients following a stroke improves the stimulation of the muscles of the dorsiflexors of the foot with a positive impact on the walking.


Eligibility criteria: Inclusion Criteria:

* Patient with a stroke occurring in a period ranging from 15 days to a month before inclusion and presenting left or right hemiplegia.
* Voluntary motricity of the dorsal flexors of the foot greater than or equal to 1 on the scale of Held and Pierrot Deseilligny
* Quadriceps voluntary motor skill greater than or equal to 2 on the scale of Held and Pierrot Deseilligny
* Informed consent of the patient.

Exclusion Criteria:

* - Evolutive neurological disease leading to cognitive impairment (Alzheimer's, Parkinson's, Multiple sclerosis ...)
* Pre-stroke neurological sequelae
* Achilles tendon elongation or tendinous transfer surgery.
* Spasticity of the sural triceps greater than 2 on the modified Ashworth scale
* Injection of botulinum toxin
* Patients under guardianship, curatorships or under safeguard of justice.
* Allergy to glue, skin lesions located on the zone of laying of the bands
* Complex Regional Pain Symptom of the Ankle

Primary outcomes:
measure: voluntary muscularity
timeFrame: Week 10
Secondary outcomes:
measure: Spasticity score
timeFrame: Week 10
Other outcomes:
Locations:
city: Toulouse
country: France
facility: University Hospital Toulouse
Study officials:
affiliation: University Hospital, Toulouse
name: Aurélie MORIN
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06316206: The Use of Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation
Official title: The Use of Ethinylestradiol/Dienogest in Random Start Rapid Preparation of Endometrium Before Office Hysteroscopic Polypectomies: a Multicenter, Prospective, Randomized Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Endometrial Polyp
Endometrial Diseases
Keywords: Hysteroscopy
Endometrial preparation
Lead sponsor: University of Palermo
Sponsor class: OTHER
Collaborators: name: University of Roma La Sapienza
First posted: 2024-03-18
Enrollment: 80
Sex: FEMALE
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The presence of a thin endometrium plays an important role in enabling the best conditions for hysteroscopic surgery. Recently, for this purpose, many studies have evaluated the effect of preoperative administration of a variety of drugs. We explored the efficacy of random started 14-day administration of Ethinylestradiol/Dienogest, in rapid preparation of endometrium for hysteroscopic polypectomy.


Eligibility criteria: Inclusion Criteria:

* Patients with endometrial polyps.

Exclusion Criteria:

* Patients with other endometrial pathologies.

Primary outcomes:
measure: Quality of endometrial preparation
timeFrame: 14th day of treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Palermo
country: Italy
facility: Andrea Etrusco
city: Roma
country: Italy
facility: Marco Monti
Study officials:
References: